Skip to main content

Recent News

Dr. John Cush
@RheumNow
Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA 14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA https://t.co/ZmxQLIqUZQ
Dr. John Cush
@RheumNow
Does a Gout Flare Increase Risk of a Cardiovascular Event? In 2022, Cipolletta and colleagues published a JAMA study showing a temporal association between gout flares and subsequent major adverse cardiovascular events (MACE). This study reported 93% higher odds of MACE in the https://t.co/C1j8n7jkf0
Dr. John Cush
@RheumNow
New FDA Approved for Polymyalgia Rheumatica - Secukinumab The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate a https://t.co/DYgQWzAMJr
Dr. John Cush
@RheumNow
Top 6 Practice-Changing Highlights from ACR26 The content at ACR Orlando was vast. We looked at several posters/listened to many talks, and heard from colleagues. So if we missed some great abstracts that will be practice-changing for you, we apologize in advance. Here is our https://t.co/CXtqE75EFG

ICYMI: Lupus Nephritis Reshapes Pregnancy Risk

Bella Mehta, MBBS, MS

Investigators presented an abstract using Epic Cosmos to examine pregnancy outcomes in women with SLE across health systems nationwide. Beyond confirming that SLE pregnancies remain higher risk, the study highlights two important opportunities: the ability to use large-scale, real-world data to study relatively uncommon outcomes in lupus, and the importance of lupus nephritis history when counseling patients and planning pregnancy.

Dr. John Cush
@RheumNow
Is It Still Inflammation? A 34 year old female has axSpA. Her CRP is 3, her MRI is quiet, and her BASDAI is 7. She has tried two biologics and is asking about a third. Before we write that prescription, #ACR26 challenges us to ask a different question: is it still inflammation? https://t.co/K4QVBx3cDa
Dr. John Cush
@RheumNow
T-Cell Engagers in Autoimmunity: CRS From 12% to 67% Across Six Reports Six ACR 2026 reports put BCMA, CD19, CD20 and gamma-delta engagers side by side in autoimmune disease. The efficacy signal is consistent. The safety signal depends almost entirely on how the molecule was https://t.co/M1Kkc08VBQ
Dr. John Cush
@RheumNow
Sjögren’s and SOB? Think About ILD! While we excitedly await FDA approval of novel immunotherapies, it is worth reminding ourselves that the new drugs will be indicated primarily for patients with active systemic manifestations of SjD that is of at least moderate severity based https://t.co/T51dAyRpcw
Dr. John Cush
@RheumNow
CD19 CAR-T Relapse: 7 of 50 in Erlangen, Rescued With BCMA Relapse after CD19 CAR-T was rare in lupus and common in anti-synthetase syndrome and Scl-70 scleroderma. Six of seven relapsing patients were treated with BCMA-directed therapy and responded again. https://t.co/SCD9wZ5DVa
Dr. John Cush
@RheumNow
New FDA Approved for Polymyalgia Rheumatica - Secukinumab The US Food and Drug Administration (FDA) approved secukinumab (Cosentyx) for the treatment of adults with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate a https://t.co/kmgEiZIiFS
Dr. John Cush
@RheumNow
A Look Ahead: Precision, Safety and Access as Therapies Grow More Complex ACR Convergence 2026 closed on a high note with the Clinical Year in Preview, a forward-looking session on the final day presented by Alexis Ogdie, MD, MSCE, of the University of Pennsylvania. https://t.co/br5LBqkqeu
×